<!-- Markdown copy of https://highpeptides.com/research/aod-9604-guide/ for AI agents. Canonical: https://highpeptides.com/research/aod-9604-guide/ -->

# AOD-9604: The “Fat Loss” Fragment: Rodent Results vs. Human Trials

📄 **5** PubMed citations

By [Steve B](https://highpeptides.com/author/editorial-team/), HighPeptides Editor

Last updated: October 2026

AOD-9604 is a synthetic peptide corresponding to amino acids 177–191 of human growth hormone (plus an added tyrosine), the C-terminal region linked to growth hormone's lipolytic activity. In obese rodents it raised lipolysis markers and reduced weight gain and body fat. In human trials it did not raise IGF-1 or impair glucose tolerance; a 12-week randomized trial reported an average 2.6 kg loss on 1 mg/day vs 0.8 kg on placebo (no dose-response: 10 mg/day lost less), but a larger 24-week trial did not show a significant weight-loss benefit over placebo. Not FDA-approved.

24 wk

Human Trial (no significant weight loss)

16

Amino Acids (Tyr + hGH 177–191)

6

Placebo-Controlled Human Trials

Short answer

AOD-9604 is a synthetic peptide matching amino acids 177–191 of human growth hormone, plus an added tyrosine, studied for fat loss. A 12-week trial reported 2.6 kg loss on 1 mg/day vs 0.8 kg on placebo, but a larger 24-week trial showed no significant weight loss vs placebo. It is not FDA-approved.

Track your vials and inventory on paper

Printable vial and inventory sheets for your own research records. Every value is entered by you. Free to build and preview; $5/month to unlock printing.

[Stacking compounds? Check interactions first →](https://highpeptides.com/interactions/)

[Build your tracker →](https://highpeptides.com/printables/builder/)

- 1What Is AOD-9604?

- 2What the Research Shows

- 3Key Takeaways

- 4Verified Research Source

- 5Recommended Products

- 6Related Resources

Background

## What Is AOD-9604?

AOD-9604 is a synthetic peptide corresponding to amino acids 177-191 of the growth hormone sequence plus an added tyrosine (the C-terminal region linked to growth hormone's lipolytic activity), designed to avoid its growth-promoting effects.

🔥

Stimulates Lipolysis

In obese mice and rats, AOD-9604 increased markers of lipolysis (the breakdown of stored fat) and fat oxidation and reduced weight gain. In humans, a 12-week randomized trial reported an average 2.6 kg loss on 1 mg/day vs 0.8 kg on placebo (no dose-response: 10 mg/day lost less), but a larger 24-week trial did not show a significant weight-loss benefit over placebo.

🚫

No IGF-1 Effect

In sponsor-run human trials, AOD-9604 did not raise serum IGF-1 or impair glucose tolerance, unlike full-length HGH. In lab assays it did not bind the growth hormone receptor or drive cell proliferation.

🛑

Anti-Lipogenic (Design Goal)

AOD-9604 was designed to keep growth hormone's anti-lipogenic signalling: slowing the synthesis and storage of fat (lipogenesis), not the creation of new fat cells. Human data showing a meaningful effect are lacking.

💉

Route & Safety

Human trials tested oral and intravenous dosing; subcutaneous injection is what online protocols describe. Sponsor-reported trials found tolerability similar to placebo, but no long-term safety data exist.

Research

## What the Research Shows

Animal and human data on AOD-9604: a 12-week human trial reported more weight loss than placebo on 1 mg/day, but the rodent fat-loss signal was not confirmed in a larger 24-week trial.

📋 Regulatory Status Research Only (US)

AOD-9604 is not FDA approved and is not approved for any indication by major regulatory agencies. FDA previously placed it in Category 2 of its compounding bulk-substance interim policy (substances that may present significant safety risks, citing possible immunogenicity, peptide-related impurity and API-characterization concerns, and serious adverse events that may be associated with AOD-9604, though causality is not clear); the nominator withdrew it, and FDA now lists it as “nominated but withdrawn.” Human efficacy results are mostly sponsor-reported rather than peer-reviewed.

Lipolysis Stimulation

Raised lipolysis markers in obese mice and rats

Animal data

IGF-1 Independence

No IGF-1 rise or glucose-tolerance impairment in human trials

Human trials

Weight Loss (Animal Studies)

Reduced body weight and body fat in obese rodent models

Demonstrated

Weight Loss (Human Trial)

No significant benefit vs placebo on the primary endpoint (24 weeks, oral)

Not shown

Source · Rats

Ng et al., Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone

Horm Res, 2000 · [PMID: 11146367](https://pubmed.ncbi.nlm.nih.gov/11146367/)

Source · Obese mice

Heffernan et al., Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment

Int J Obes Relat Metab Disord, 2001 · [PMID: 11673763](https://pubmed.ncbi.nlm.nih.gov/11673763/)

Source · Obese mice, body fat

Heffernan et al., The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice

Endocrinology, 2001 · [PMID: 11713213](https://pubmed.ncbi.nlm.nih.gov/11713213/)

Source · Human safety, IGF-1, glucose

Stier, Vos & Kenley, Safety and tolerability of the hexadecapeptide AOD9604 in humans (six randomized placebo-controlled trials)

J Endocrinol Metab, 2013;3(1-2):7-15 · [journal page](https://www.jofem.org/index.php/jofem/article/view/157) (not PubMed-indexed)

Source · 12-week human trial result

Valentino, Lin & Waldman, Central and peripheral molecular targets for antiobesity pharmacotherapy (review)

Clin Pharmacol Ther, 2010 · [PMID: 20445536](https://pubmed.ncbi.nlm.nih.gov/20445536/)

Source · 24-week human trial, dosing, approval status

Dominikowski et al., The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis (review)

Front Endocrinol, 2026 · [PMID: 42395176](https://pubmed.ncbi.nlm.nih.gov/42395176/)

Source · FDA compounding status

FDA, Certain bulk drug substances for use in compounding that may present significant safety risks

U.S. Food and Drug Administration, content current as of 04/22/2026 · [fda.gov](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks)

Bottom Line

## Key Takeaways

What We Know

- HGH fragment (amino acids 177-191)

- Raised lipolysis markers and cut weight gain in obese rodents

- Did not raise IGF-1 or impair glucose tolerance in human trials

- A 12-week trial reported 2.6 kg vs 0.8 kg loss (1 mg/day, no dose-response); a larger 24-week trial showed no significant weight loss vs placebo

- Did not bind the GH receptor or drive cell proliferation in lab assays

What We Don't Know

- Limited peer-reviewed human efficacy data (mostly sponsor-reported)

- Not FDA approved in US

- Optimal dosing protocols not established

- Long-term safety unknown

## Verified Research Source

Research compounds from Swiss Chems, our affiliate supplier.

[Browse Swiss Chems →](https://swisschems.is/?ref=6587&campaign=highpeptides&sub_id=hp-aod-9604-guide)

Code **HIGHPEP10**: 10% off regular-priced items

Affiliate links support HighPeptides at no extra cost. Swiss Chems publishes third-party HPLC COAs for selected products (vendor-published, a claim to verify).

## Recommended Products

[ **💉 Insulin Syringes** For peptide research ](https://www.amazon.com/s?k=insulin+syringes+29g&tag=meetpeptide20-20) [ **💧 Bacteriostatic Water** For peptide reconstitution ](https://swisschems.is/product/bacteriostatic-water-bac/?ref=6587&campaign=highpeptides&sub_id=hp-aod-9604-guide) [ **🧴 Alcohol Swabs** Injection prep ](https://www.amazon.com/s?k=alcohol+swabs&tag=meetpeptide20-20) [ **⚖️ Smart Scale** Track weight progress ](https://www.amazon.com/s?k=smart+scale&tag=meetpeptide20-20)

## Related Resources

[**💪 Follistatin Guide**](https://highpeptides.com/research/follistatin-344/) [**📖 Peptide Encyclopedia**](https://highpeptides.com/encyclopedia/) [**🧮 Dosing Calculator**](https://highpeptides.com/calculator/)

Trusted Vendor

### Research-Grade Peptides

Research compounds from Swiss Chems, our affiliate supplier; vendor-published COAs for selected products.

[Browse Swiss Chems →](https://swisschems.is/?ref=6587&campaign=highpeptides&sub_id=hp-aod-9604-guide)

Code **HIGHPEP10**: 10% off regular-priced items

Affiliate links support HighPeptides at no extra cost.

📚

### Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place.

[Get the Guide: $19 (normally $29) →](https://highpeptides.com/ebooks/complete-peptide-protocol-guide/) [The Peptide Buyer’s Playbook ($19)](https://highpeptides.com/buyers-playbook/)

Important Disclaimer

This page is for **educational purposes only**. AOD-9604 is not FDA approved. Always consult a healthcare provider.

📘

### Get the Free 2026 Peptide Protocol Stack

Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.
